Seattle Genetics is earning attention, in the field of cancer treatment investigative research. The company CEO, who is also the company President, is Clay Siegall. Dr. Siegall co-founded the institute in 1998. His other responsibility, falls under being appointed, as the chairperson of the Seattle Genetics board committee. He is known for having a deep passion for helping to improve the lives of people, who suffer from cancer, since he began his vocation into biomedical research. Dr. Siegall is known by his peers, as a tireless worker, who has personally lead the institute, to a great many advances in the field of cancer studies, including, revolutionary treatments for cancer survivors.
After Dr. Siegall earned his Ph.D. from George Washington University, majoring in the field of Genetics, he accumulated a number of career accomplishments. When he started out, as a Senior Research Investigator, he worked at the Pharmaceutical Research Institute, owned by Bristol-Myers. He soon, earned a promotion to the status of Leading Scientist, until advancing in the ranks to Staff Fellow, as well as, Biotechnology Fellow, both at the National Cancer Institute. These accomplishments fueled his desire to found his own company, Seattle Genetics. Company stock prices have essentially tripled in value in only a 5 year period.
Dr. Siegall is known for his commitment to focusing on cancer research, while using only the most modern equipment. Seattle Genetics, is the first institute, to create antibody-drug conjugates, which earned them the FDA’s approval in 2011. With their recent expansion, they are able to assist cancer survivors, in over 60 countries. Dr. Siegall is renowned, for his leadership role in raising in excess of 1.2 billion dollars, for Seattle Genetics, from both private and public funding. This influx of revenue has helped to create new advances for treating cancer survivors, by using only the most cutting-edge technology.
Dr. Clay Siegall, earned the Alumnus of the Year award, for Natural Sciences and Math, from the University of Maryland in 2013. Dr. Siegall has made numerous contributions to the scientific community, such as, publishing new methods and treatments for cancer patients.